论文部分内容阅读
人急性早幼粒细胞白血病动物模型，至今尚未见报导。我们将体外培养的人急性早幼粒白血病细胞袜ＮＢ４细胞（Ｍ３型）１×１０￣６，接种在ｓｃｉｄ小鼠腹腔内，种后一个月，腹腔内长出腹水，以后每间隔３周用腹水传代，各代小鼠接种成活率为１００％，目前已传３５代．各代小鼠存活期稳定，平均存活时间为２１，６±２．３天。对ｓｃｉｄ－ＡＰＬ－Ａ细胞作生物学特性观察，其形态学、免疫学、细胞遗传学及分子学都有体外培养的ＮＢ４细胞的特点。用全反式维甲酸（ＡＴＲＡ）治疗ｓｃｉｄ－ＡＰＬ－Ａ小鼠时，产生诱导分化作用，腹水细胞的ＮＢＴ还原反应及细胞膜表面分化抗原均有所增加，同时治疗组的ｓｃｉｄ小鼠平均存活时间较对照组的明显延长。此外还观察到治疗ＡＰＬ常用药物阿霉素对ｓｃｉｄ－ＡＰＬ－Ａ也有较强的生长抑制作用。上述结果表明。己建成的ｓｃｉｄ－ＡＰＬ－Ａ可以用于评价新药或巳知治疗ＡＰＬ药物的动物模型。
The human acute promyelocytic leukemia animal model has not yet been reported. We in vitro cultured human acute promyelocytic leukemia socks NB4 cells (M3 type) 1 × 10 ~ 6, inoculated in the abdominal cavity of scid mice, one month after planting, ascites grow in the abdominal cavity, after every interval of 3 weeks Ascites passage, the survival rate of mice inoculated in each generation was 100%, and it has been transmitted for 35 generations. Each generation of mice has a stable survival period with an average survival time of 21,6±2.3 days. The biological characteristics of scid-APL-A cells were observed in morphology, immunology, cytogenetics, and molecular biology with the characteristics of NB4 cells cultured in vitro. When all-trans retinoic acid (ATRA) was used to treat scid-APL-A mice, differentiation was induced, and NBT reduction and cell membrane surface differentiation antigens were increased in ascites cells, and the mean survival time of scid mice in the treatment group was also increased. It is significantly longer than the control group. In addition, it has been observed that the treatment of APL, a commonly used drug, doxorubicin, also has a strong growth inhibitory effect on scid-APL-A. The above result shows. The established scid-APL-A can be used to evaluate new drugs or animal models that are known to treat APL drugs.